Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 220 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Norepinephrine Clear all
Completed Phase 3 Interventional Results available

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00633880
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 1:22 PM EDT
Recruiting Phase 4 Interventional

Identifying and Treating Depression in the Orthopaedic Trauma Population

NCT05976347
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine 20 MG, Duloxetine 30 MG, Observation
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 4 Interventional

Solriamfetol and CBT-I in Patients With Insomnia Disorder

NCT05838430
View directory record Official record
Conditions
Insomnia
Interventions
Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
Drug · Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Enrolling by invitation Phase 2 Interventional

Droxidopa / Pyridostigmine in Orthostatic Hypotension

NCT01370512
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
Droxidopa, Pyridostigmine, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

NCT00547911
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
Interventions
Droxidopa, Carbidopa, Entacapone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 2, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01328002
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Early Phase 1 Interventional

Vasopressor Outcomes in Spine Surgery

NCT06053398
View directory record Official record
Conditions
Hypotension
Interventions
Phenylephrine, Norepinephrine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 2, 2026, 1:22 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT03567447
View directory record Official record
Conditions
Parkinson Disease, Falls Patient
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 2, 2026, 1:22 PM EDT
Not yet recruiting Phase 4 Interventional

Phenotype Guided Vasoactive Medication During Kidney Transplantation

NCT07633600
View directory record Official record
Conditions
Kidney Transplant, Fluid Management
Interventions
Phenotype-Guided Vasoactive Management
Drug
Lead sponsor
Jennifer Cutler
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Major Depression

NCT00420004
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, Escitalopram
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

NCT02015546
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Vilazodone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 2, 2026, 1:22 PM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

NCT02495545
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
CSFD and elevation of MAP, Maintenance of MAP
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

NCT00983814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Droxidopa+Carbidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 2, 2026, 1:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Stress Hormones on Emotion and Cognition

NCT00032838
View directory record Official record
Conditions
Healthy
Interventions
Yohimbine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03005 vs Pristiq

NCT03733574
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 2, 2026, 1:22 PM EDT
Enrolling by invitation Phase 4 Interventional

The GUARDIAN Trial - Vasopressor Sub-Study

NCT04934748
View directory record Official record
Conditions
Blood Pressure
Interventions
Routine Blood Pressure Management, Tight Blood Pressure Management, Phenylephrine, Norepinephrine
Procedure · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years and older
Enrollment
6,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Locus-coeruleus Function in Normal Elderly and AD Risk

NCT04403165
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Nocturnal polysomnography (NPSG), Lumbar Puncture (LP), PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB), Psychomotor Vigilance Task (PVT)
Procedure · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Doxazosin for Cocaine Dependence

NCT01145183
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 2, 2026, 1:22 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Hand Perfusion and Pulse Oximetry Performance

NCT06925646
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Finger hyperperfusion via adenosine, Finger hypoperfusion via by norepinephrine, Baseline hypoxic test
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 2, 2026, 1:22 PM EDT
Withdrawn Not applicable Interventional

Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

NCT03952494
View directory record Official record
Conditions
Depression
Interventions
Genomind®Professional PGx Express TM
Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 2, 2026, 1:22 PM EDT